NervGen Stock Climbs with Trial Approaching, Cash Burn Still a Focus
NervGen Pharma Corp. was up almost 4% to $3.70 in midday Nasdaq trade Wednesday, lifted by its latest quarterly update as the company preps for its late-stage RESTORE trial. Shares moved between $3.58 and $3.75 and about 59,940 shares were traded. NervGen is moving from lining up with regulators to actually starting work. The company said this week it’s got an agreement with the U.S. Food and Drug Administration on RESTORE, the registrational study of NVG-291 for chronic tetraplegia, where all four limbs are paralyzed. CEO Adam Rogers said NervGen is “firmly in execution mode.” Site activation has started, and the study is still on track to kick off in mid-2026.